Renaissance Capital logo

Anchiano Therapeutics Priced, Nasdaq: ANCN

Late-stage biotech developing therapies for early-stage bladder cancer.

Industry: Health Care

Latest Trade: $4.60 0.00 (0.0%)

First Day Return: -6.1%

Return from IPO: -60.0%

Industry: Health Care

We are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard treatment for early-stage bladder cancer, which is one of the most prevalent forms of cancer. We have discovered and are developing a biologic agent called inodiftagene vixteplasmid, or inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in efficacy and problematic in toxicity. Bladder cancer is a disease that typically causes symptoms early in its course and consequently presents the patient and the treating physician with an opportunity to gain control of the malignancy. However, the limitations of existing therapies, developed in the 1970s, often result in a prolonged series of unsuccessful treatments that can end in the radical removal of the bladder. Our lead product candidate, inodiftagene, is a recombinant DNA construct that will be administered to patients whose therapy for early stage bladder cancer has failed: this is gene therapy for bladder cancer. Preclinical studies and clinical trials completed so far have demonstrated that our product candidate can deliver a lethal gene specifically to bladder cancer cells in a patient’s bladder.
more less
IPO News for Anchiano Therapeutics
more
IPO Data
IPO File Date 01/07/2019
Offer Price $11.50
Price Range $11.50 - $11.50
Offer Shares (mm) 2.7
Deal Size ($mm) $31
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/12/2019
Offer Price $11.50
Price Range $11.50 - $11.50
Offer Shares (mm) 2.7
Deal Size ($mm) $31
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Jerusalem, Israel
Founded 2004
Employees 17
Website www.anchiano.com